KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

被引：0
作者：
F Loupakis
A Ruzzo
C Cremolini
B Vincenzi
L Salvatore
D Santini
G Masi
I Stasi
E Canestrari
E Rulli
I Floriani
K Bencardino
N Galluccio
V Catalano
G Tonini
M Magnani
G Fontanini
F Basolo
A Falcone
F Graziano
机构：
[1] Unit of Medical Oncology 2,Istituto Toscano Tumori and Department of Oncology
[2] Azienda-Ospedaliero Universitaria Pisana,Department of Biomolecular Sciences
[3] Transplantes and New Technologies in Medicine,Division of Pathology, Department of Surgery
[4] University of Pisa,undefined
[5] Section of Biochemistry and Molecular Biology “G. Fornaini”,undefined
[6] University of Urbino,undefined
[7] Unit of Medical Oncology,undefined
[8] University Campus Biomedico,undefined
[9] Via Alvaro del Portillo 200 – 00128 Rome,undefined
[10] Italy,undefined
[11] Mario Negri Institute for Pharmacological Research,undefined
[12] Via La Masa 19 – 20156 Milan,undefined
[13] Italy,undefined
[14] Unit of Medical Oncology,undefined
[15] San Raffaele Scientific Institute,undefined
[16] Via Olgettina 60 – 20132 Milan,undefined
[17] Italy,undefined
[18] Unit of Medical Oncology,undefined
[19] Hospital of Pesaro,undefined
[20] Via Lombroso 1 – 61100 Pesaro,undefined
[21] Italy,undefined
[22] University of Pisa,undefined
[23] Istituto Toscano Tumori,undefined
[24] Via Roma 67 – Pisa,undefined
[25] Italy,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
colorectal cancer; cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：715 / 721
页数：6
相关论文
共 277 条
  • [1] Adam R(2009)Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27 1829-1835
  • [2] Wicherts DA(2009)American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091-2096
  • [3] de Haas RJ(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634
  • [4] Ciacio O(1989)Ras oncogenes in human cancer: a review Cancer Res 49 4682-4689
  • [5] Levi F(2007)Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf Structure 15 1618-1629
  • [6] Paule B(2005)The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma Gut 54 1283-1286
  • [7] Ducreux M(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345
  • [8] Azoulay D(2008)Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705-5712
  • [9] Bismuth H(2006)Recurrent KRAS codon 146 mutations in human colorectal cancer Cancer Biol Ther 5 928-932
  • [10] Castaing D(1988)Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins Mol Cell Biol 8 2472-2478
12345678910